Dipal Doshi - 01 Mar 2026 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Reporting relationship: CEO, Director
Issuer ticker: TRDA
Reported as of: 01 Mar 2026
Net transaction value: -$340,551
SEC form: 4
Accepted by SEC: 03 Mar 2026, 18:21:25 UTC
Prior SEC filing: 06 Feb 2026
Next SEC filing: 03 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Jared Cohen, as Attorney-in-Fact

Key filing fact

Dipal Doshi filed Form 4 for Entrada Therapeutics, Inc. (TRDA) on 03 Mar 2026.

Key facts

This page summarizes Dipal Doshi's Form 4 filing for Entrada Therapeutics, Inc. (TRDA).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Mar 2026, 18:21.

Change

Previous filing in this sequence was filed on 06 Feb 2026.
Current net transaction value: -$340,551.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001613084 Primary reporting owner

Doshi Dipal

Relationship: CEO, Director
Address: C/O ENTRADA THERAPEUTICS, INC., ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON
Signature: /s/ Jared Cohen, as Attorney-in-Fact
Signature date: 03 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TRDA transaction

Common Stock

Award

Transaction value: $0
Shares: +139,400
Change %: +34%
Price: $0.000000
Shares after: 555,064
Date: 01 Mar 2026
Ownership: Direct
Footnotes: F1

TRDA transaction

Common Stock

Tax liability

Transaction value: $115,052
Shares: -9,869
Change %: -1.8%
Price: $11.66
Shares after: 545,195
Date: 02 Mar 2026
Ownership: Direct
Footnotes: F2, F3

TRDA transaction

Common Stock

Tax liability

Transaction value: $225,500
Shares: -19,181
Change %: -3.5%
Price: $11.76
Shares after: 526,014
Date: 03 Mar 2026
Ownership: Direct
Footnotes: F2, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TRDA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +208,000
Change %
Price: $0.000000
Shares after: 208,000
Date: 01 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 208,000
Exercise price: $11.93
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

Footnote F2

Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.17 to $11.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.22 to $12.095, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F5

25% of the option shares shall vest and become exercisable on March 1, 2027, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2030.